Association of Centre of Excellence Self-Administered Questionnaire (CESAM) Score and Frailty Levels

Association of Centre of Excellence Self-AdMinistered Questionnaire (CESAM) Score and Frailty Levels With Incident Adverse Health Events in Older Community Dwellers: Results of the NuAge Study

This study evaluates the association of the Self-Administered questionnaire (CESAM) score and its stratification of frailty in four levels with incident adverse health events in older community dwellers and to compare this association with three validated frailty indexes which are the Cardiovascular Health Study frailty index, Study of Osteoporotic Fracture index and Rockwood frailty index.

Study Overview

• Status: Active, not recruiting
• Conditions: Chronic Disease; Frailty; Disability Physical
• Intervention / Treatment: Other: Frailty evaluation

Detailed Description

Older adults' health and functional status is heterogeneous because of the various cumulative effects of chronic diseases and physiologic decline, contributing to a vicious cycle of increased frailty. Thanks to advances in medicine and hygiene, a growing number of older adults spend more years with a greater range of disorders causing disability but not mortality. Health systems thus need to face this new challenge. Quantification of frailty and its association with the occurrence of adverse health events is crucial to understand how efficiently health systems may respond to this situation.

This study aims to examine the association of the CESAM score and its stratification of frailty in four levels with incident adverse health events in older community dwellers and to compare this association with a) five validated frailty indexes which are the Cardiovascular Health Study frailty index, Study of Osteoporotic Fracture index, Rockwood frailty index, 6-item brief geriatric assessment (BGA) and "Program of Research on the Integration of Services for the Maintenance of Autonomy" (PRISMA-7) and b) two new frailty indexes developed over the COVID-19 pandemic which are "Évaluation SOcio-GÉriatrique" (ESOGER) and "CriblAge et REcommandations" (CARE).

• Study Type: Observational
• Enrollment (Estimated): 1741

Contacts and Locations

Study Locations

• Canada
  • Quebec
    • Montréal, Quebec, Canada, H3T 1E2
      • Jewish General Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 67 years to 82 years (Older Adult)
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

• Healthy community-dwellers from Quebec, Canada
• A follow-up during 4 years

Description

Inclusion Criteria:

-Healthy community-dwellers from Quebec, Canada

Exclusion Criteria:

-Community-dwellers from outside Quebec, Canada

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Frailty	It will be used a questionnaire called:The Centre of Excellence Self-Administered questionnaire(CESAM). This questionnaire evaluates frailty of older adults by providing a score and a stratification of frailty in 4 levels (Vigorous versus mild, moderate and severe frailty).	the questionnaire will be used once, after 4 years follow-up.

Collaborators and Investigators

• Sponsor: Jewish General Hospital
• Investigators: Principal Investigator: Olivier Beauchet, MD, Jewish General Hospital

Study record dates

Study Major Dates

• Study Start (Actual): July 23, 2019
• Primary Completion (Actual): December 15, 2021
• Study Completion (Estimated): January 1, 2025

Study Registration Dates

• First Submitted: May 23, 2019
• First Submitted That Met QC Criteria: May 23, 2019
• First Posted (Actual): May 24, 2019

Study Record Updates

• Last Update Posted (Actual): April 5, 2024
• Last Update Submitted That Met QC Criteria: April 4, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Disease Attributes; Chronic Disease; Frailty
• Other Study ID Numbers: 2020-1793

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No